Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07616128
Recruiting Phase 2

Study of EVO756 in Adults With Migraine

NCT07616128 · tracked via the Priya Life Science USA tracker
Sponsor
Evommune, Inc
Phase
Phase 2
Started
2026-07-29
Last updated
2026-10-02

Condition(s) studied

Migraine

Investigational drug(s) / intervention(s)

EVO756, Dose 1EVO756, Dose 2Placebo

EVO756, Dose 1: Orally administered EVO756, Dose 1 (Daily)

EVO756, Dose 2: Orally administered EVO756, Dose 2 (Daily)

Placebo: Placebo Control (Daily)

Study summary

This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.

Eligibility

Sex
ALL
Min age
18 Years
Max age
64 Years
Healthy volunteers
No
Key Inclusion Criteria: * Adults aged 18 to \<65 years * Migraine with or without aura, per ICHD-3 criteria * History of failure with prior preventive migraine treatments * Not currently using migraine preventive therapy Key Exclusion Criteria: * Difficulty distinguishing migraine from other headache types or presence of other primary headache disorders * Use of certain medications * Any clinically significant medical, psychiatric, neurological, cardiovascular, or laboratory abnormalities

Primary outcome measure(s)

  • Mean change from baseline in the number of monthly migraine days (MMD) — Last month of the 12-week treatment period

Trial sites (35)

FacilityCityRegionStatus
Trialsphere Corp Chandler Arizona Recruiting
Buena Park Research Center Buena Park California Recruiting
Neuro Pain Research Center Fresno California Recruiting
CA Medical Clinic for Headache Los Angeles California Recruiting
Diablo Clinical Research dba Flourish Research Walnut Creek California Recruiting
Hasbani Neurology New Haven Connecticut Recruiting
New England Institute for Neurology and Headache Stamford Connecticut Recruiting
Clinical Neuroscience Solutions, Inc. Jacksonville Florida Recruiting
Apple Medical Research Group, Inc Miami Florida Recruiting
Blessed Healthcase & Research Miami Florida Recruiting
Florida Research Center, Inc. Miami Florida Recruiting
Clinical Neuroscience Solutions, Inc. Orlando Florida Recruiting
Vantage Clinical Trials Tampa Florida Recruiting
Premiere Research Institute at Palm Beach Neurology West Palm Beach Florida Recruiting
Clinical Integrative Research Center of Atlanta Atlanta Georgia Recruiting
Accel Research Site-Decatur-Alcanza Decatur Georgia Recruiting
Neurology Center of New England P.C. Foxborough Massachusetts Recruiting
Mass Institute of Clinical Research Westborough Massachusetts Recruiting
Michigan Headache and Neurological Institute Ann Arbor Michigan Recruiting
Quest Research Institute-Alcanza Farmington Hills Michigan Recruiting
Bio Behavoural health Toms River New Jersey Recruiting
Clinosis - Dent Neurologic Instite Amherst New York Recruiting
Asheville Neurology Specialists, Pa Asheville North Carolina Recruiting
Eximia Research NC Raleigh North Carolina Recruiting
NeuroScience Research Center Canton Ohio Recruiting
Clinical Trials of South Carolina Charleston South Carolina Recruiting
Campbell Clinical Research Franklin Tennessee Recruiting
FutureSearch Trials of Neurology Austin Texas Recruiting
FutureSearch Trials of Dallas Dallas Texas Recruiting
SFF Medical Research Group LLC Houston Texas Recruiting
Mercury Clinical Research Inc. - Houston Neurology Associates Houston Texas Recruiting
MedStar Health: Headache Center at McLean McLean Virginia Recruiting
Vaught Neurological Services Crab Orchard West Virginia Recruiting
Centre de Recherche St-Louis Québec Quebec Recruiting
Momentum Clinical Research - Wellington Wellington New Zealand Recruiting

Other trials for the same condition

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine Active, not recruiting
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine Recruiting
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine Active, not recruiting
A Comprehensive Digital Care Program for Migraine Management Enrolling by invitation
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07616128 on ClinicalTrials.gov ↗ ← All trials in the USA